Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

4.3 Exposure–response for safety While the exposure–unbound E2 relationship showed a trend of lower E2 with increasing vilaprisan exposure, the E2 concentrations mostly remained within the physiologic range for the follicular phase and E2 levels returned to baseline for all patients in both ASTEROID 1 8 and ASTEROID 2. 9 Although a decrease in E2 levels will contribute to ovulation inhibition and consequently to induction of amenorrhoea, 6 the potential effect of a decrease in E2 levels on long‐term safety is considered to be of higher clinical relevance.
Previous and recent multicenter, randomized controlled trials showed a trend towards reduced mortality in favor of V‐V ECMO over conventional treatment. 6 , 7 Furthermore, in a recently published meta‐analysis of these trials, 60‐day mortality was significantly lower in the V‐V ECMO group. 8 Although mortality rates in V‐V ECMO are lower compared with other ECMO modalities, a substantial quote of patients still die during hospital admittance. 9 According to the Extracorporeal Life Support Organization (ELSO), more than 75 000 ECMO runs for respiratory compromise have been performed in more than 450 centers (as of July 2021).
In general, during the entire drought period, S‐D showed a trend towards lower values than L‐D (Figure S4 ), but no statistical differences were observed at any date of measurement. 3.3 Rewatering period Since irrigation was re‐started at different times for L‐D and S‐D containers, we present the g s and A N data in parallel as days of rewatering (DOR) to permit a direct comparison between L and S (Figure 3 ).
In addition, mRNA-vaccinated patients who were treated with thiopurines showed a trend towards lower antibody concentrations compared to patients who were not treated with thiopurines (geometric mean [95% confidence interval]: 4523 [3574-5724] vs . 5634 [4561-6958] AU/ml, P=0.182).
When compared to the RP240 model, the RP340 model showed a trend of improved correlation with the manual grading for the measurement of EZ width (correlation coefficient changed to 0.988 from 0.981), increased linear regression slope (changed to 0.951 from 0.930), and reduced CoR (changed to 0.582 mm from 0.728 mm).
Similar to the HCRU, the overall annual HCRU direct cost also showed a trend toward highest mean AD-related HCRU gross cost (per patient) among moderate-to-severe treated AD cohort (531.5 USD) followed by the mild-to-moderate treated AD cohort (378.4 USD) and lowest for the untreated AD cohort (144.0 USD).
r antagonists, renin–angiotensin–aldosterone system inhibitors and angiotensin receptor neprilysin inhibitor (ARNI) might be used for patients with mildly reduced left ventricular ejection fraction ( HFmrEF; 41–49%), but with a IIB class of recommendation.[ 1 ] Indeed, the PARAGON-HF trial recently showed a trend towards better outcomes in HFpEF patients treated with sacubitril/valsartan (an ARNI) compared to valsartan, especially in the lower end of the left ventricular ejection fraction (LVEF) spectrum, in women, in patients recently hospitalised for HF, and in those with higher high sensitivity troponin values at baseline.[ 3 – 7 ] However, while the Food and Drug Administration has approved sacubitril/valsartan use in patients with ‘below normal’ LVEF, the European Medicines Agency has not.
Forty-seven patients were classified as responders (excellent and indeterminate responses) and incomplete responders (biochemical and structurally incomplete responses) by assessing the RTT at 1.5 years follow-up similar to recommendation of 2015 adult DTC ATA guidelines. Results Female-to-male ratio showed a trend of gradual increase with increasing age.